NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
Voltar para busca
Dado oficial do USPTO
OXURION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
27/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
25/06/2018
Data de registro
11/06/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/12/2025
Última transação
27/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
32
Localização do titular
BE
Examinador
MESSICK, TABITHA LEE
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Oxurion NV
ThromboGenics
Representantes
Martin W. Schiffmiller Kirschstein Israel Schiffmiller & Pieroni, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Biopharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; diagnostic medical reagents, chemicals preparations and biological materials all the foregoing being in the form of spatially defined arrays and solutions and reagents for medical laboratory use in diagnosting, monitoring, and predicting diseases and for measuring and predicting response to therapy of cardiac and vascular diseases; pharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; pharmaceutical substances and medicines for treatment or prevention of eye disorders and diseases and of ophthalmological disorders and diseases; pharmaceutical preparations and substances for the treatment or prevention of diabetes; medicines for treating or preventing diabetes; ophthalmic medicines and surgical fluids, ophthalmic pharmaceutical preparations; pharmaceutical eye drops
Classe 42
Scientific and technological services, namely research and design relating thereto in the field of ophthalmology, in the field of diabetes and in the field of treatment of cardiovascular disease, cardiac disease and vascular disease; industrial analysis of the pharmaceutical preparations of others used for the treatment of ophthalmologic diseases, diabetes and cardiovascular diseases for quality control purposes; research services in the field of ophthalmology, diabetes and cardiovascular diseases; pharmaceutical and biopharmaceutical research and development; biopharmaceutical product evaluation; research in the field of treatment of cardiovascular disease, cardiac disease, and vascular disease; development of new treatments for pathologies in which vascular biology plays a critical role in the field of biopharmaceuticals
Classe 44
Medical services; veterinary services; consultancy services, namely, consultancy in the medical, veterinary and pharmaceutical treatment of patients in the fields of ophthalmology, diabetes and cardiovascular diseases; medical services, namely, cardiac and vascular therapeutic, prognostic and diagnostic testing services
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
C71T
CANCELLED SECTION 71
26/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/11/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
11/06/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/10/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
21/09/2019
FIMP
FINAL DISPOSITION PROCESSED
21/09/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/09/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
13/06/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
11/06/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/03/2019
PUBO
PUBLISHED FOR OPPOSITION
26/03/2019
GPNX
NOTIFICATION PROCESSED BY IB
23/03/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/03/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/03/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/03/2019
ALIE
ASSIGNED TO LIE
15/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/02/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/01/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/01/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/01/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/01/2019
RFNT
REFUSAL PROCESSED BY IB
09/11/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/10/2018
RFRR
REFUSAL PROCESSED BY MPU
25/10/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/10/2018
CNRT
NON-FINAL ACTION WRITTEN
13/10/2018
DOCK
ASSIGNED TO EXAMINER
13/10/2018
MAFR
APPLICATION FILING RECEIPT MAILED
28/08/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/08/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/08/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OXURION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.